Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen plus panretinal photocoagulation vs panretinal photocoagulation alone in high-risk proliferative diabetic retinopathy
2009-016760-36Phase 2Completed
- Sponsor
- AIBILI
- Start
- Nov 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegaptanib sodium in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by AIBILI. Primary endpoint: Regression of retinal neovascularization. Started Nov 2009; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2009-016760-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016760-36.